| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-12-15 | Evotec (Germany) Spero Therapeutics (USA - MA) | new therapeutics for Gram-negative bacteria | research - development | Infectious diseases | Research agreement | |
| 2015-12-14 | Pierre Fabre Médicament (France) Inserm (France) | new therapeutic targets in immuno-oncology | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-12-14 | Sanofi (France) MAB Discovery (Germany) | monoclonal antibodies | R&D licensing |
R&D agreement | ||
| 2015-12-14 | Amgen (USA - CA) GSK (UK) | Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab) | metastatic colorectal cancer, postmenopausal women with osteoporosis at high risk for fracture, increase of bone mass in men with osteoporosis at high risk for fracture, prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors, giant cell tumor of bone, hypercalcemia of malignancy refractory to bisphosphonate therapy | product acquisition |
Bone diseases - Cancer - Oncology | Product acquisition |
| 2015-12-14 | Complix (Belgium) Selexis (Switzerland) | CMX-02 | manufacturing production |
Autoimmune diseases - Cancer - Oncology | Production agreement | |
| 2015-12-14 | RuiYi, now Bird Rock Bio (USA - CA) | name change |
Establishment of a new subsidiary in the EU | |||
| 2015-12-14 | Intellia Therapeutics (USA - MA) | nomination |
Technology - Services | Nomination | ||
| 2015-12-11 | Crispr Therapeutics (Switzerland - UK) | nomination |
Nomination | |||
| 2015-12-11 | Biophytis (France) | sarcopenic obesity, age related macular degeneration | nomination |
Nomination | ||
| 2015-12-11 | Intercept Pharmaceuticals (USA - NY) | nomination |
Nomination | |||
| 2015-12-11 | Prima Biomed (Australia) Yamaguchi University (Japan) NEC Corporation (Japan) | IMP321 and therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University | hepatocellular carcinoma and different carcinomas | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-12-10 | Novo Nordisk (Denmark) IBM (USA - NY) | diabetes care solutions built on the Watson Health Cloud | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2015-12-10 | Biosafe (Switzerland) StemLife Bhd(Malaysia) | cord blood processing technologies | distribution supply |
Technology - Services | Distribution agreement | |
| 2015-12-10 | BioInvent (Sweden) Cancer Research Technology (CRT) (UK) University of Southampton (UK) | IgG2B | licensing |
Cancer - Oncology | Licensing agreement | |
| 2015-12-09 | Tiziana Life Sciences (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-09 | The Medicines Company (USA - NJ) | resignation |
Resignation | |||
| 2015-12-09 | PTC Therapeutics (USA - NJ) Massachusetts General Hospital (USA - MA) | compounds modulating alternative splicing of the IKBKAP pre-mRNA | rare genetic disorders resulting from pre-mRNA splicing defects including familial dysautonomia | collaboration R&D |
Rare diseases - Genetic diseases | Collaboration agreement |
| 2015-12-08 | BMS (USA - NY) Princeton University (USA - NJ) | collaboration R&D |
Collaboration agreement | |||
| 2015-12-08 | MDxHealth (Belgium) SouthGenetics (Uruguay) | ConfirmMDx® for Prostate Cancer | prostate cancer | commercialisation |
Cancer - Oncology - Diagnostic | Commercialisation agreement |
| 2015-12-08 | Takeda Pharmaceutical (Japan) Cour Pharmaceutical (US - IL) | novel immune modulating therapies based on Tolerizing Immune Modifying nanoParticle (TIMP) platform | celiac disease | development |
Autoimmune diseases - Digestive diseases | Development agreement |
